COCP
Price:
$2.52
Market Cap:
$25.64M
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocr...[Read more]
Industry
Biotechnology
IPO Date
2012-02-22
Stock Exchange
NASDAQ
Ticker
COCP
According to Cocrystal Pharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.37. This represents a change of 37.23% compared to the average of -1.00 of the last 4 quarters.
The mean historical PE Ratio of Cocrystal Pharma, Inc. over the last ten years is -91.90. The current -1.37 PE Ratio has changed 49.07% with respect to the historical average. Over the past ten years (40 quarters), COCP's PE Ratio was at its highest in in the December 2017 quarter at 7.04. The PE Ratio was at its lowest in in the September 2015 quarter at -218.70.
Average
-91.90
Median
-7.59
Minimum
-519.67
Maximum
-0.00
Discovering the peaks and valleys of Cocrystal Pharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 13.88%
Maximum Annual PE Ratio = -0.00
Minimum Annual Increase = -99.77%
Minimum Annual PE Ratio = -519.67
Year | PE Ratio | Change |
---|---|---|
2023 | -0.00 | -99.77% |
2022 | -0.41 | -99.16% |
2021 | -48.58 | -47.95% |
2020 | -93.32 | 2.25% |
2019 | -3.97 | 92.96% |
2018 | -2.06 | -99.13% |
2017 | -236.14 | 6.32% |
2016 | -3.68 | -67.17% |
2015 | -11.20 | -97.84% |
2014 | -519.67 | 13.88% |
The current PE Ratio of Cocrystal Pharma, Inc. (COCP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-16.33
5-year avg
-29.26
10-year avg
-91.90
Cocrystal Pharma, Inc.’s PE Ratio is greater than ZIVO Bioscience, Inc. (-5.50), greater than RenovoRx, Inc. (-3.51), less than Tempest Therapeutics, Inc. (-0.62), less than Ikena Oncology, Inc. (-1.24), greater than Catalyst Biosciences, Inc. (-28.21), less than Moleculin Biotech, Inc. (-0.22), greater than Pulmatrix, Inc. (-2.29), less than Cyclacel Pharmaceuticals, Inc. (-0.06), less than Akari Therapeutics, Plc (-0.61), less than Quoin Pharmaceuticals, Ltd. (-0.28), less than Blue Water Vaccines, Inc. (-0.01), less than PaxMedica, Inc. Common Stock (-0.03), less than Revelation Biosciences, Inc. (-0.05), less than Hillstream BioPharma, Inc. (-0.99), less than Onconova Therapeutics, Inc. (-0.08), less than Bio-Path Holdings, Inc. (-0.30), less than Allarity Therapeutics, Inc. (-0.08), less than Kiromic BioPharma, Inc. (-1.17), less than Virax Biolabs Group Limited (-0.57), less than Biodexa Pharmaceuticals Plc (-0.16),
Company | PE Ratio | Market cap |
---|---|---|
-5.50 | $78.37M | |
-3.51 | $30.96M | |
-0.62 | $37.39M | |
-1.24 | $73.83M | |
-28.21 | $19.42M | |
-0.22 | $5.81M | |
-2.29 | $22.14M | |
-0.06 | $2.00M | |
-0.61 | $11.90M | |
-0.28 | $2.45M | |
-0.01 | $3.41M | |
-0.03 | $696.27K | |
-0.05 | $2.51M | |
-0.99 | $4.17M | |
-0.08 | $20.90M | |
-0.30 | $4.48M | |
-0.08 | $4.50M | |
-1.17 | $1.47M | |
-0.57 | $7.47M | |
-0.16 | $996.56M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cocrystal Pharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cocrystal Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Cocrystal Pharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for Cocrystal Pharma, Inc. (COCP)?
What is the highest PE Ratio for Cocrystal Pharma, Inc. (COCP)?
What is the 3-year average PE Ratio for Cocrystal Pharma, Inc. (COCP)?
What is the 5-year average PE Ratio for Cocrystal Pharma, Inc. (COCP)?
How does the current PE Ratio for Cocrystal Pharma, Inc. (COCP) compare to its historical average?